denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: independent educational grants from AbbVie, Bristol Myers Squibb, and Geron.
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Research, MDS, Clinical Practice (Health Services and Quality), Workforce, Education, Chronic Myeloid Malignancies, Diseases, Treatment Considerations, Adverse Events, Myeloid Malignancies, Biological Processes
Hematology Disease Topics & Pathways:
Research, MDS, Clinical Practice (Health Services and Quality), Workforce, Education, Chronic Myeloid Malignancies, Diseases, Treatment Considerations, Adverse Events, Myeloid Malignancies, Biological Processes
Friday, December 6, 2024: 7:00 AM-10:00 AM
San Diego Ballroom AB
(Marriott Marquis San Diego Marina)
Chair:
Guillermo Garcia-Manero, MD, The University of Texas MD Anderson Cancer Center
Disclosures:
Garcia-Manero: Astex: Other: Personal fees; Aprea: Research Funding; H3 Biomedicine: Research Funding; Amphivena: Research Funding; Bristol Myers Squibb: Other: Personal fees, Research Funding; Onconova: Research Funding; Helsinn: Other: Personal fees; Forty Seven: Research Funding; Astex: Research Funding; Merck: Research Funding; Helsinn: Research Funding; Janssen: Research Funding; Curis: Research Funding; Genentech: Research Funding; Genentech: Other: Personal fees; AbbVie: Research Funding; Novartis: Research Funding.
Speakers:
Maria Diez-Campelo, MD, PhD, University Hospital of Salamanca, IBSAL
and
Valeria Santini, MD, AOU Careggi, University of Florence
Disclosures:
Diez-Campelo: ASTEX/OTSUKA: Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL TO MEETINGS; CURIS: Membership on an entity's Board of Directors or advisory committees; SYROS: Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Advisory board fees; Gilead: Other: Travel reimbursement; HEMAVAN: Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; KEROS: Honoraria, Membership on an entity's Board of Directors or advisory committees; BLUEPRINT MEDICINES: Consultancy, Membership on an entity's Board of Directors or advisory committees; AGIOS: Consultancy, Membership on an entity's Board of Directors or advisory committees.
This CME/MOC/AAPA activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the HealthTree Foundation for MDS.
In collaboration with our partner the HealthTree Foundation for MDS, PeerView’s unique Seminars & Tumor Board live event will pair compelling case scenarios and collaborative decision-making (designed to mimic the back-and-forth of real-world tumor boards) with practice-changing evidence to provide guidance on the skills and strategic planning that inform treatment individualization across the spectrum of MDS management—while addressing real-world barriers that can prevent accurate patient assessment and hinder the delivery of modern therapeutic standards. Throughout the activity, a panel of leading MDS experts will collaboratively illustrate:
- Updated methods for diagnosis, symptom identification, and prognostic assessment
- The informed selection of innovative therapies as standard 1L management of MDS anemia, in the care of ESA-refractory patients, and in settings defined by specific mutations (eg, TP53 mutations) or cytogenetics
- Team-based strategies for effective and continuous delivery of care, including appropriate dosing, safety management, and judicious therapeutic sequencing in both LR- and HR-MDS settings
Join our experts to elevate your MDS management and standards of care!
See more of: Friday Satellite Symposia